Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150 , February 2012

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors

  • Arlene Chan

      Affiliations

    • Mount Medical Centre, 41, 146 Mounts Bay Rd, Perth, Western Australia 6000, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 618 94814522; fax: +61 618 94814544.
    • ,
  • Shailendra Verma

      Affiliations

    • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    • ,
  • Sibylle Loibl

      Affiliations

    • German Breast Group, Neu-Isenburg, Germany
    • ,
  • Jeffrey Crawford

      Affiliations

    • Duke University Medical Center, Durham, NC, USA
    • ,
  • Mi Rim Choi

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Lyndah Dreiling

      Affiliations

    • Amgen Inc., Thousand Oaks, CA, USA
    • ,
  • Ted Vandenberg

      Affiliations

    • University of Western Ontario, London, ON, Canada

,Accepted 11 March 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1040-8428(11)00070-9

doi: 10.1016/j.critrevonc.2011.03.003

Critical Reviews in Oncology / Hematology
Volume 81, Issue 2 , Pages 136-150 , February 2012

Article Tools

* Image Usage & Resolution